What’s Next In HCV? Gilead Thinks It Has More To Offer
Executive Summary
With the current crop of therapies having achieved the “holy grail” of all-oral, short-regimen treatment with excellent efficacy and safety, there’s a lot of pressure on the next generation of hepatitis C therapies.